Skip to content

Protara Therapeutics, Inc.

TARA· NasdaqCore metricsCIK 1359931

Biological products, except diagnostic substances175 peers

Last sale
Oct 15, 2026 · -4.22%
Market cap
$143.02M
59.97M shares
Filings
812
$2.95M
FY 2014
—
-$21.69M
Q3 2026N/M FY25 yoy
-$23.15M
Q3 2026N/M FY25 yoy
-$56.23M
Q3 2026derivedN/M FY25 yoy
-$0.35
Q3 2026N/M FY25 yoy
$25.15M
Q3 2026−69.5% FY25 yoy
$143.02M
—
—
1.0×
-39.48%
—

FY2025 figures · derived

Price

$2.3955.50%$2.98past year
Oct 15, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$2.95MFY 2014
$2.95M0FY 2014
PeriodEndedValueKindSource trail
FY 20142014-12-31$2,948,000reported

Capital returns

Dividends and buybacks · FY2021 to FY2023
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2023—$91.00K$91.00K—11.43M sh+1.1%—
FY2022—$90.00K$90.00K—11.31M sh+0.5%—
FY2021—$228.00K$228.00K—11.25M sh+0.2%—

Biological products, except diagnostic substances

Protara Therapeutics, Inc. is the 102nd largest of the 176 covered companies the SEC files under this code, by market cap. SIC 2836

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Protara Therapeutics, Inc. · CIK 1359931 · Engraved from SEC EDGAR